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Research in the last decade has revolutionized the way in which we view mitochondria. Mitochondria are no longer
viewed solely as cellular powerhouses; rather, mitochondria are now understood to be vibrant, mobile structures,
constantly undergoing fusion and fission, and engaging in intimate interactions with other cellular compartments
and structures. Findings have implicated mitochondria in a wide variety of cellular processes and molecular
interactions, such as calcium buffering, lipid flux, and intracellular signaling. As such, it does not come as a surprise
that an increasing number of human pathologies have been associated with functional defects in mitochondria.
The difficulty in understanding and treating human pathologies caused by mitochondrial dysfunction arises from
the complex relationships between mitochondria and other cellular processes, as well as the genetic background of
such diseases. This review attempts to provide a summary of the background knowledge and recent developments
in mitochondrial processes relating to mitochondrial-associated metabolic diseases arising from defects or
deficiencies in mitochondrial function, as well as insights into current and future avenues for investigation.
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General roles of mitochondria in metabolism
In its most traditional definition, the mitochondrion is
the energy-generating organelle of the cell, responsible
for the final steps of metabolizing organic substances to
produce energy for the cell in the form of adenosine tri-
phosphate (ATP). In mammalian cells, most of the redox
potential used for generating ATP arrives at the mito-
chondrion in the form of the nicotinamide adenine
dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2), reduced coenzymes generated by the accept-
ance of electrons derived from the breakdown of organic
substances in the tricarboxylic acid (TCA) cycle. Four
protein complexes in the inner membrane make up the
electron transport chain (ETC, also known as the elec-
tron transport system), which converts the redox energy
stored as NADH and FADH2 into chemical energy in
the form of ATP. In brief, complexes I and II receiveCorrespondence: j.mcinnes@jacobs-university.de
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reproduction in any medium, provided the orelectrons donated from NADH and FADH2, respectively,
followed by their shuttling to complexes III and IV, and
their final donation onto an oxygen molecule, yielding
H2O. Additional proteins can transfer electrons from
donors to the ETC, including electron-transferring-flavoprotein
dehydrogenase (member of a pathway receiving elec-
trons from β-oxidation and amino acid catabolism)
[1], and CHCHD4, which receives electrons from
disulfide bridges [2]. As electrons are shuttled through
the complexes I, III and IV by electron carriers, protons
(H+) are moved from the mitochondrial matrix into the
intermembrane space. This creates a net positive charge
in the intermembrane space, and a net negative charge
in the matrix. This electrochemical gradient is respon-
sible for providing the driving force needed to produce
ATP [3].
F1F0-ATP synthase is a large enzyme complex made
up of over 22 subunits. The preferred route for protons
in the intermembrane space to re-enter the matrix, in an
attempt to flow down the gradient and re-establish equi-
librium, is to enter through the ATP synthase enzyme
complex. As protons flow through the channel domain
of ATP synthase, a motor force is generated, which is
used to rotate a large, rotating catalytic domain facingThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
McInnes Nutrition & Metabolism 2013, 10:63 Page 2 of 13
http://www.nutritionandmetabolism.com/content/10/1/63the matrix, which couples adenosine diphosphate (ADP)
to an inorganic phosphate moiety (Pi) to yield ATP [4].
Experiments using purified enzymes from cows and yeast
revealed that the number of protons required by ATP syn-
thase to make a single ATP molecule is almost twice as
high for lower eukaryotes as it is for animals [5]. Thus, the
production of ATP by the ATP synthase enzyme has sig-
nificantly increased in efficiency during the evolution of
multicellular organisms from early eukaryotic ancestors.
Mitochondria most readily produce ATP by the oxida-
tion of NADH and FADH2 yielded from the breakdown of
sugars such as glucose. In mammals, however, a second
energy source comes from the degradation of fatty acids,
some of which are liberated from lipid reserves, for ex-
ample in adipocytes. Fatty acids, which are often found
in chains as CoA-esters, are first transported across the
outer mitochondrial membrane by palmitoyl transferase I,
resulting in translocation to the intermembrane space and
transformation into an acyl-carnitine form. Subsequently,
acyl-carnitines are translocated across the inner mitochon-
drial membrane by cartinine acyl translocase. Once in the
matrix, acyl-carnitines are converted back to their original
acyl-CoA form by palmitoyl transferase II, which can be
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into thyminfour matrix-localized enzymes, and results in the acyl-
CoA entering the citric acid cycle to yield NADH and
FADH2, which are utilized by the ETC for ATP production
[7]. In humans, β-oxidation is a major energy source, and
defects in this process, or in the ETC in general, can lead
to ATP deficiency, as explored further below (Table 1).
The mitochondrial life cycle: fusion, fission, and
autophagy
Mitochondria cannot be synthesized de novo, and thus
new mitochondria must arise from existing mitochon-
dria. Similar to a cell growing before division, a mito-
chondrion elongates and increases in volume before
septation, which results in two physically separate mito-
chondria (Figure 1). This process is termed mitochon-
drial fission. Notably, mitochondria also have the ability
to fuse together, joining membranes and compartments
to yield a single larger mitochondrion. Mitochondrial
fusion and fission occur throughout the life cycle of the
cell, meaning that at any time point, mitochondria are in
a dynamic flux between fusion and fission. It is believed that
this balance of fusion and fission gives rise to the diverse
mitochondrial sizes and structures visible when observ-
ing mitochondrial morphology [8].g in mitochondrial-associated metabolic diseases
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Figure 1 The mitochondrial life cycle. Since mitochondria cannot be synthesized de novo, they must arise from existing mitochondria.
Mitochondrial biogenesis is the process by which mitochondria increase in size, accompanied by lipid synthesis and assembly of ETC subunits.
One mitochondrion can divide into two physically distinct mitochondria by the process of fission, which requires the mechanical force of the ER
and the Drp1 protein, which is recruited to mitochondria by the Mff receptor. Two mitochondria can also join together to become one mito-
chondrion with continuous inner- and outer-membranes in a process termed mitochondrial fusion, which requires the proteins Mfn1, Mfn2, and
OPA1. In the case of mitochondrial damage, indicated by decreased ETC activity, oxidizing membrane potential, and accumulation of ROS and
unfolded proteins, a mitochondrion may be degraded by mitophagy. The marking of mitochondria for degradation is facilitated by the NIX/LC3
pathway during erythrocyte differentiation, and by the Pink1/Parkin pathway in other cell types.
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relatively well described, including the GTPases Mfn1,
Mfn2 and OPA1. The mitofusins Mfn1 and Mfn2, along
with a dynamin-related GTPase OPA1, are three proteins
required for mitochondrial fusion in mammals. Mitofusins
localize to the outer mitochondrial membrane, where they
facilitate outer membrane fusion, while OPA1 localizes to
the inner membrane, where it facilitates inner membrane
fusion. Mfn1 and Mfn2 are required to be on both
mitochondria for fusion to occur, while OPA1 present
on only one of the two mitochondria is sufficient for inner
membrane fusion [9]. As the two mitochondrial objects
approach each other, the inner and outer mitochondrial
membranes fuse simultaneously, preventing contents of
the matrix and intermembrane space from mixing, and
thereby maintaining mitochondrial function.
The opposite process of mitochondrial fusion is fission,
whereby one mitochondrion divides and results in two
physically distinct mitochondria. In contrast to fusion, the
key players in mitochondrial fission require more in-
vestigation, as the current picture is incomplete. Most
recent evidence implicates the dynamin-related Drp1
protein to play the central role in mitochondrial fis-
sion, by the use of a GTPase domain to catalyze a
membrane-pinching action similar to the mechanism
of vesicle endocytosis [10]. Interestingly, Drp1 localizes
to the cytosol, suggesting the presence of a mitochon-
drial membrane-bound receptor to recruit Drp1. Des-
pite initial reports that the Fis1 protein plays the role
of a Drp1 receptor [11], most recent evidence suggests
the Mff protein plays this role, and has been shown to
be essential for Drp1 recruitment [12]. Most recently,
the picture of mitochondrial fission has become even
more complex with the finding that the mitochondrial
interactions with the endoplasmic reticulum (ER) playsa role in the recruitment of Drp1 to Mff receptors,
and possibly provides a mechanical force to facilitate
fission [13]. This finding adds to the growing list of
processes that are mediated by mitochondria-ER inter-
actions (see below).
It is known that the function of the dynamin-related
GTPases involved in mitochondrial fission work simi-
larly to those involved in other membrane-restricting
processes, such as the fission of peroxisomes. However,
exactly which proteins play key roles in this process, as
well as how and when they are recruited and regulated,
as well as their interaction at mitochondria-ER contact
sites, remains a large feat for future research. Addition-
ally, deficiencies or mutations in any of the players in
mitochondrial fusion or fission are implicated in severe
pathologies. For example, it has been shown that a muta-
tion in OPA1, required for mitochondrial fusion, leads to
deficits in mitochondrial respiration and ultimately death
in retinal ganglion cells, resulting in blindness [14].
Mitochondrial fission is not only important for the
division of mitochondria; it is also used as a mitochon-
drial waste disposal system, which is crucial for main-
taining mitochondrial respiration. Throughout its lifetime,
a mitochondrion can accumulate damage and debris,
characterized by excessive amounts of reactive oxygen
species (ROS) and dysfunctional proteins, often leading
to uncoupled electron transport chains. One way mito-
chondria can dispose of such molecular debris is by seg-
regating that part of the mitochondrion by fission,
followed by its recruitment into an autophagosome for
mitophagy [15].
Mechanisms for mitophagy in mammals have been
highly conserved from yeast, and are believed to be a
vital mechanism for preventing metabolic disease in
humans [16,17]. Upon loss of membrane potential, the
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recruiting the ubiquitin ligase Parkin, which creates ubi-
quitin tags on the mitochondrion, marking it for degrad-
ation and recruiting an autophagosomal membrane to
the mitochondrion [18]. Eventually, the autophagosome
will fuse with a lysosome, at which point its contents will
be degraded and recycled. This process has been well
understood in red blood cells, which utilize a similar
pathway for the depletion of mitochondria during the
maturation of reticulocytes into erythrocytes [19]. Dur-
ing erythrocyte maturation, the NIX protein attaches to
mitochondria and recruits the LC3 protein, which is
bound to an autophagosomal membrane to encircle the
mitochondrion for degradation [16].
Finally, defects in mitophagy have been linked to hu-
man pathologies associated with metabolism such as
ageing, cancer, neurodegenerative disease, and tissue in-
jury and repair [17,20]. Additionally, mitophagy now ap-
pears to be one pathway to suppress mitochondrial
DNA (mtDNA) mutations [21]. Growing evidence pro-
vides more linkages between mitophagy and a number
of cellular functions and pathologies [22], highlighting
the importance of further investigating mitophagy in the
context of metabolic disease.
Maintenance of mtDNA is critical for metabolic function
Though mitochondria are estimated to have entered host
cells some 2 billion years ago, the integration of mtDNA
elements into the nuclear genome appears to be an on-
going process [23]. Mitochondria contain, on average,
2–10 mtDNA molecules, depending on their state within
the fusion-fission cycle [24]. Because human mtDNA
lacks mutation-suppressing elements such as intron se-
quences, it is estimated that mtDNA has a 10-fold
higher accumulation of mutations than nuclear DNA
[25]. Moreover, the small size of mtDNA molecules
(approximately 16.5 kb in humans) increases the fre-
quency of primary mutations in mtDNA sequence,
which may result in ETC deficiencies and thus lead to
impaired mitochondrial function. Mechanisms regulat-
ing the upkeep of mtDNA are therefore of paramount
importance in maintaining mitochondrial fitness and
preventing disease [26,27].
Damage to mtDNA is, in large part, caused by ROS
generated within the mitochondrion. Considering the rela-
tively high local concentration of ROS and the significant
impact of mutations in mtDNA, this is a dangerous
combination. Though the mitochondrion contains no
DNA maintenance machinery of its own, it was discov-
ered that many nuclear-encoded proteins involved in
DNA maintenance and repair are also targeted to mito-
chondria [28]. The best characterized DNA repair mech-
anism in mitochondria is base excision repair, whereby a
damaged (improperly paired) base is excised, the gap isfilled, and the new base is ligated onto the recipient nu-
cleotide [29]. Additionally, nuclear proteins required for
nucleotide excision repair in the nucleus also localize to
mitochondria upon dysfunction, hinting that this path-
way may exist in mitochondria [30].
Another problem the mitochondrion must circumvent
is single- or double-strand DNA breaks, caused by
ROS-induced sugar damage, or by the failure of topoiso-
merases to relieve torsional stress following transcrip-
tion. Single-strand DNA breaks recruit enzymes common
to base excision repair to repair the damaged 5′ and 3′
nucleotides, along with the tyrosyl-DNA phosphodiester-
ase 1 (TDP1) protein, which repairs breaks originating
during DNA replication, at which time most single-
strand breaks occur [31]. Double-stranded breaks in nu-
clear DNA are extremely deleterious to the cell, and
therefore the nucleus has developed three pathways to
repair such breaks in nuclear DNA, including end-
joining and homologous recombination [28]. Preliminary
evidence has suggested that these repair pathways may
also function in mitochondria [32,33]. Finally, mitochon-
dria have the ability to repair insertion-deletion loops,
arising from base-base mismatches, by a mismatch repair
pathway [34].
When the mitochondrion is unable to repair mtDNA
damage, the mitochondrion may segregate damaged
mtDNA into a region of the mitochondrion which, fol-
lowing fission, will immediately decrease in respiratory
activity and will be targeted for mitophagy, destroying
the damaged mtDNA molecules within [16]. As an ex-
treme and rare last alternative, excessive amounts of
mutated and/or unrepaired mtDNA may trigger apop-
tosis of the entire cell [35]. As a functional system,
mechanisms for mtDNA maintenance and repair thus
play a critical role in maintaining mitochondrial fitness.
Mitochondrial metabolism varies among tissues
Like differentiated cells, mitochondria are specialized to
perform specific functions within tissues. For example,
mitochondria in the liver are primarily biosynthetic,
while in the heart mitochondria are primarily ATP gen-
erating. The co-evolution of mitochondria within tissues
has led to the development of mechanisms for nuclear-
encoded proteins to control many mitochondrial func-
tions, greatly contributing to metabolic homeostasis in
humans [36]. Though evidence strongly supports the nu-
cleus controlling many of the mitochondrion’s activities,
the mechanisms behind many putative pathways remain
undefined. Some nuclear-encoded proteins, such as
mitochondrial transmembrane carrier proteins for glu-
tamate and ATP-Mg/Pi exchange, have been found to
vary among species and tissues, often coinciding with the
specialized function of that particular cell type [37]. An-
other identified modification is the hyper-phosphorylation
Figure 2 ER and mitochondria interact intimately to perform
cellular functions. (A) ER-mitochondria contact sites mediate a
variety of processes. ER-mitochondria contact sites are sites of lipid
and calcium exchange, used for modifying membrane lipids and
sequestering calcium ions for modulating mitochondrial function as
targets of intracellular signaling cascades. Such contact sites are also
thought to be regulators of mitochondrial fission in a recent
hypothesis that holds that ER extensions aid in the recruitment of
Mff and Drp1 to mitochondria, and furthermore provide mechanical
force for fission. Additionally, recent findings show that the ER and
mitochondria are inherited in a co-dependent manner in yeast,
facilitated by the Mmr1 protein, which binds mitochondria to
cortical ER sheets in the yeast bud tip. (B) In response to an external
stimulus indicating cellular stress, calcium ions sequestered in the ER
lumen are released into the cytosol by the transmembrane inositol
1,4,5-triphosphate receptor protein. Released calcium ions then enter
ER-tethered mitochondria by an unknown transmembrane calcium
channel located in the outer mitochondrial membrane, followed by
translocation into the mitochondrial matrix by the mitochondrial
calcium uniporter. The targets of calcium ions in the matrix primarily
include energy-producing processes, but can also lead to apoptosis
in cases of severe cellular stress.
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plexes in cardiac muscle cells, which stimulates ETC ac-
tivity and thereby ATP production [38]. Additionally, the
differential or tissue-specific expression of proteins such as
transporters or gene regulatory proteins is one way in which
mitochondria of different cell types can be specialized.
Within tissues, mitochondria also participate in signal-
ing by calcium buffering. One of the most important
physiological roles of mitochondria, aside from ATP pro-
duction, is the storage of calcium (Ca2+) ions. Calcium
ions enter mitochondria by a calcium ion uniporter,
where they are sequestered. The speed and mechanism
by which calcium ions are released from mitochondria
back into the cytosol are highly variable among mito-
chondria of different tissue types [39]. Since very small
(nanomolar) fluctuations in cytosolic calcium ion
concentration have the ability to influence signaling
pathways, and thereby alter the cell’s physiology, the
sequestration of calcium ions within mitochondria pro-
vides an important control over intracellular signaling.
As discussed above, increased mitochondrial calcium
levels also stimulate ATP synthesis, and thus there is a
direct link between calcium sequestration within mito-
chondria and mitochondrial respiratory activity at the
level of the ETC.
ER-mitochondria interactions mediate cellular processes
Mitochondria and ER are not stand-alone, independently
functioning organelles. Rather, their close interaction is
crucial for a number of processes including mitochon-
drial fission, calcium buffering, lipid flux, and organelle
inheritance (Figure 2A) [40,41]. Mitochondria and ER
exchange a number of lipids, some which contribute to
mitochondrial membrane elongation, and others which
are chemically modified in the mitochondrion and then
translocated back to the ER [42]. Dysfunctions in lipid flux
are also a hallmark of several cardiovascular diseases
which are also closely linked to deficits in ETC activity,
and thus further identifying elements involved in ER-
mitochondrial lipid exchange is of great interest [41,43].
Perhaps one of the most important functions of ER-
mitochondria contact sites is the regulation of mito-
chondrial fission. It is thought that the ER encircles
mitochondria, providing an initial constriction before
the Drp1 protein provides the mechanical force to carry
out fission [12,13,44]. It may also be that the ER regu-
lates the recruitment of proteins required for fission,
such as Drp1, to mitochondria from the cytosol. Re-
search in recent years has greatly increased our under-
standing of the physical and functional relationship
between the ER and mitochondria, and the next focus
will be to further investigate the molecular mechanisms
facilitating these interactions, how these interactions
may be altered in mitochondrial-associated diseases.In addition to lipid flux, ER-mitochondria contact sites
are crucial for calcium buffering between the two organ-
elles. Early studies showed that increased calcium efflux
from the ER directly resulted in increased mitochondrial
calcium levels, thereby establishing that ER and
mitochondria can exchange calcium ions in a regulated
fashion (Figure 2B) [45]. Mitochondria and ER
both sequester calcium ions, which can later be released
into the cytosol, thereby activating calcium-dependent
signaling pathways involved in a multitude of processes
[46]. As discussed above, mitochondria are not only
storage organelles for calcium ions, but are also targets
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chondrion’s metabolic activity and other processes
[47,48]. It is thought that a key function of calcium ex-
change is to activate calcium-dependent mitochondrial
processes, such as the TCA cycle, made possible by the
high concentration of calcium ions in the ER in contrast
to the cytosol. Another likely function is that mitochon-
dria and ER can co-regulate calcium ion release for cel-
lular signaling, especially when a high concentration of
calcium is required, such as the activation of the apop-
totic cascade [49,50]. Fluctuations in calcium concentra-
tion is also an activator of mitochondrial fission at
ER-mitochondria contact sites, thus necessitating a
nearby calcium source [8,41].
In summary, interactions between mitochondria and
the ER have been implicated in almost all mitochondrial
processes, further adding to the complexity of mitochon-
drial function in health and in pathogenesis. These key
processes, described here, are likely working in concert
with one another to synergistically regulate mitochon-
drial and ER function. Most importantly, calcium buffer-
ing at ER-mitochondria contact sites directly influences
ETC activity, and thereby influences mitochondrial
respiration.
Diet and nutrition influence mitochondrial processes
Diet and nutrition have the ability to influence mito-
chondrial function, and in turn the effects of mitochon-
drial-associated diseases. As discussed, energy sources
provided by diet include carbohydrates and fats. Carbo-
hydrates are broken down by the glycolysis pathway and
TCA cycle to yield reduced NADH and FADH2, which
are shuttled to the ETC for ATP production. Fats, on
the other hand, are broken down by β-oxidation to yield
reduced NADH and FADH2, as well as acetyl-CoA,
which will enter the TCA cycle. Additionally, in the liver
and kidneys, ketone bodies are produced as a byproduct
of fatty acid β-oxidation. Ketone bodies are high-energy
compounds, which can be transported via the blood to
other tissues, where they are processed and enter the
TCA cycle [6,7]. Ketone bodies thus have the ability to
serve as an alternative energy source for tissues in situa-
tions of impaired glucose oxidation.
Though clinical data investigating how diet influences
mitochondrial function is currently quite limited, one
well studied diet associated with influencing mitochon-
drial function is the ketogenic diet. The ketogenic diet is
a diet rich in fat and low in carbohydrates, designed to
stimulate ketone body biogenesis by replacing carbohy-
drates with fats as a primary energy source. As discussed
below, many mitochondrial pathologies arise from de-
fects in mitochondrial metabolism. In some cases of dis-
ease, mutations affect proteins required for glucose
oxidation (also causing ETC inhibition), leading to theinability of glucose to serve as a primary carbon source.
In these cases, the use of a ketogenic diet in patients has
been reported to be an effective therapy for treating im-
paired glucose oxidation, since stimulating fatty acid oxi-
dation in mitochondria bypasses the glucose oxidation
pathway and provides a glucose-independent energy
source [51]. In this type of therapy, ketone bodies can
serve as an energy-providing source in cases where the
processing of carbohydrates becomes compromised. In
one well studied example, a ketogenic diet has been suc-
cessful in treating epilepsy, a symptom of mitochondrial
ETC defects in hippocampal neurons [51].
Most studies investigating how diet modulates mito-
chondrial function have been performed in rodent, fly
and cell line models harboring wild-type mtDNA, or
mtDNA carrying mutations associated with known
metabolic diseases. In laboratory models, ketone bodies
have been shown to promote the replication and transla-
tion of wild-type mtDNA in conditions of heteroplasmy,
in which a cell or individual harbors both wild-type and
mutated mtDNA copies [52]. In a mouse model of a
mitochondrial myopathy, it was shown that a ketogenic
diet positively affects mitochondrial function and par-
tially relieves some effects of mitochondrial myopathies
[53]. More recently, some laboratory studies have fo-
cused on how diet composition in terms of protein, fat
and carbohydrate amounts influence mitochondrial
function. For example, in a Drosophila model of im-
paired ETC function, a high carbohydrate to protein ra-
tio triggered the appearance of mitochondrial defects
[54]. Therefore, there is some evidence that alterations
in diet may have the ability to alleviate certain mito-
chondrial phenotypes in disease patients.
Despite a growing number of clinical and laboratory
examples of diet’s effect on mitochondrial function, little
is known about how this effect is brought about from a
biochemical basis. However, further study into how diet
influences mitochondrial function is likely to be very
fruitful for developing novel therapies. As discussed
below, nearly all mutations and defects associated with
mitochondrial pathologies result in decreased activity of
ETC complexes. Currently, in order to treat these dis-
eases, researchers and clinicians must first identify the
individual mutations and proteins involved in the path-
ology before attempting to design a therapy, which will
only be useful for treating that specific form of disease.
In contrast, diet appears to be able to directly influence
mitochondrial metabolism, and therefore may have the
ability to alleviate or suppress metabolic defects associ-
ated with mitochondrial pathologies. Therefore, by de-
veloping a diet regiment which increases metabolic
function in cases of defects in mitochondrial function,
one single diet plan may have the ability to treat a wide
range of mitochondrial pathologies.
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mitochondrial defects
Mitochondrial myopathy
Mitochondrial myopathy (also: mitochondrial encepha-
lomyopathy) is a disease in which mitochondria within
muscle fibers exhibit defects in function and dynamics,
leading to weakness of the muscle and accumulation of
mitochondria within the fiber, giving rise to the charac-
teristic “ragged red” fibers seen upon Gömöri trichrome
staining. Some patients experience mitochondrial myop-
athy as constant muscle weakness, while others only ex-
perience weakness upon more intense exercise, and in
some forms is accompanied by other more intense
symptoms, such as epilepsy [55]. Mitochondrial myop-
athies most commonly arise from mtDNA mutations
leading to defects in oxidative phosphorylation, and
thereby ATP production, in muscle fibers. The mtDNA
mutations causing myopathies are most frequently either
large-scale deletions or point mutations in genes encod-
ing tRNAs, rRNAs, or proteins (Figure 3) [56]. In most
cases, only a portion of mtDNA molecules within
mitochondria carries the responsible mutations, while
other copies are non-mutated [57]. Additionally, muta-
tions in gene products associated with maintaining
proper mitochondrial dynamics lead to disturbances in
mitochondrial biogenesis and fusion, resulting in theFigure 3 Mutations affecting oxidative phosphorylation are the found
(red) in genes critical for mitochondrial processes (green) lead to mitochon
(including subunits of ETC complexes) and 22 tRNAs on a circular genome
Mutations within the D-loop region, or in the POLG gene, lead to defects in
MNGIE, mutations in the nuclear TYMP gene, which encodes a protein invo
due to an unbalanced nucleotide pool. Mitochondria that have no mtDNA
mtDNA, leading to defects in oxidative phosphorylation. In another examp
mutations in genes encoding proteins required for CoQ synthesis lead to C
resulting in defects in oxidative phosphorylation. Finally, mutations in mtDN
essential for mitochondrial gene expression, lead to defects in the synthesi
comprise the majority of mutations associated with mitochondrial-associat
with lactic acidosis, MELAS, and mitochondrial myopathies.accumulation of mitochondria within fibers and the
“ragged red” phenotype.
Mitochondrial myopathies are difficult to detect, as
clinical symptoms of mitochondrial disorders often
present with many other effects, such as liver failure,
stroke-like symptoms, diabetes or other symptoms.
Thus, it is difficult to estimate the actual number of pa-
tients with mitochondrial myopathy, and what portion
of these cases is inherited or sporadic. However, it is es-
timated that approximately 12.48 per 100,000 individuals
are affected by mitochondrial disorders or are at risk to
develop such a disorder, and a significant portion of
these are expected to present symptoms of mitochon-
drial myopathies [58]. Some therapies to treat mitochon-
drial myopathies have been clinically investigated, such
as the incorporation of satellite cells carrying wild-type
mtDNA into myocytes during wound healing [56], or
the transplantation of embryonic myocytes containing
wild-type mtDNA in an attempt to decrease mutant
copy number [59]. Other treatment possibilities, such as
switching to a ketogenic diet to suppress the effects of
myopathies, are currently being investigated [53]. Des-
pite these attempts, there remains today no clinical
treatment for mitochondrial myopathies. Because mito-
chondrial myopathies affect nearly every organ system,
the characterization and treatment of myopathies remainsation of mitochondrial-associated metabolic disorders. Mutations
drial-associated diseases (blue). Human mtDNA encodes 13 proteins
. A D-loop region is the site of mtDNA polymerase gamma binding.
mtDNA replication and eventually mtDNA depletion. In the case of
lved in nucleotide synthesis, also lead to defects in mtDNA replication
copies can no longer synthesize ETC subunits encoded by the
le of a mutation in a nuclear gene affecting mitochondrial function,
oQ deficiency and therefore defects in electron transfer in the ETC,
A genes themselves, including genes encoding ETC subunits or tRNAs
s of ETC protein subunits or non-functional complexes. Such mutations
ed diseases (excluding POLG mutations), and have been associated
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[60]. As described below, mutations in a wide variety of
genes, all of which directly or indirectly affect mitochon-
drial respiratory function, often lead to myopathy-like
symptoms, characterized by muscle weakness and dys-
function in a wide variety of organs, such as the heart, kid-
neys, and intestine.
Chronic lactic acidosis
Mutations in genes encoding mitochondrial proteins re-
quired for the assembly and function of ETC complexes,
as well as the use of certain prescription drugs and other
physiological stress conditions have all been associated
with the onset of LA [61]. Lactic acidosis (LA) is charac-
terized by the buildup of lactate due to decreased mito-
chondrial respiration, which can lead to the acidification
of tissues. In healthy human cells, ATP is preferentially
generated aerobically by mitochondrial respiration.
However, due to a genetic or functional defect in the
mitochondrial ETC, cells must switch from respiration
to glycolysis in an attempt to compensate for the ATP
deficit resulting from mitochondrial dysfunction. There-
fore, patients have higher than normal lactate levels,
which can lead to acidification of tissues. What exactly
causes defects in mitochondrial function is unknown;
however, the defect appears to be present upon inherit-
ance of mitochondria from the mother, as many cases
are congenital. Nonetheless, some cases are also spor-
adic or induced, for example in the case of patients tak-
ing metformin, a drug prescribed to treat diabetes [62].
Patients suffering from high lactate levels can suffer
from tissue acidification if left untreated. The acidifica-
tion of tissues can cause system-wide disturbances in
physiological function, and thus it is critical that chronic
LA is detected and treated. Currently available treatments
include the administration of ion-containing fluids to help
raise systemic pH back to near-normal levels [63]. Most
patients suffering a chronic form of LA are well treated
and no acidification is detectable, even though systemic
lactate levels can be up to five times higher than in healthy
patients. However, upon acute illness such as infection or
consumption of metformin, blood pH may lower and
cause symptoms including vomiting, deep and rapid
breathing, and pain in the abdominal region (caused by
impaired intestinal function) [64].
MELAS
Myopathy, encephalopathy, lactic acidosis, and stroke-
like episodes (MELAS) are characterized by stroke-like
episodes and seizures, along with other myopathy-like
symptoms such as fatigue and muscle weakness [65].
MELAS onset begins before age 40, and is progressive
and fatal. In 80% of cases, patients carried a single
mtDNA point mutation affecting complex I and/ortRNA function, and is thus inherited from the mother
[66,67]. MELAS patients also show symptoms of LA.
Like many mitochondrial-associated pathologies, it is
difficult to clinically identify and there is currently no
treatment available [60].
CoQ deficiency
The mitochondrial coenzyme Q10 (CoQ) is an essential
component of the electron transport chain, shuttling elec-
trons between mitochondrial complexes I and II, and from
electron-transferring-flavoprotein dehydrogenase (ETF-
DH) to complex III, and acts as an anti-oxidant and
required cofactor for pyrimidine biosynthesis [68]. Muta-
tions in the nuclear COQ2, PDSS1/2, and ADCK3/CABC1
genes, all of which encode enzymes that are required for
CoQ biosynthesis, can lead to deficiencies in CoQ [69].
CoQ deficiency is detectable by high-performance liquid
chromatographic analysis of skeletal muscle tissue, and
presents symptoms such as skeletal muscle breakdown,
muscle weakness, seizures, migraines, ptosis (i.e. the
drooping/falling of a body part), and lactic acidosis [70]. In
contrast to most other mitochondrial-associated disorders,
CoQ deficiency can be treated by oral supplements of
CoQ in the case of COQ2 mutations, or riboflavin supple-
ments in the cases of ETFDH mutations [69]. Patients
with CoQ deficiencies due to PDSS2, COQ9, and some
other closely associated mutations have not shown posi-
tive responses to CoQ supplements [71]. Thus, while the
treatment of CoQ deficiency has had success in many
cases, there are still some cases where treatments need to
be identified.
mtDNA depletion syndrome
MtDNA depletion syndrome (MDS) is characterized by
the severe decrease in mtDNA levels in mitochondria of
various tissues. The main gene products of mtDNA are
required for proper assembly and function of the re-
spiratory chain complexes, and thus its depletion results
in severe ETC dysfunction in nearly every tissue,
resulting in a severe systematic depletion of ATP. Con-
genital mutations manifest upon birth, when the new-
born’s metabolism switches from anaerobic to aerobic
[72]. Mutations in any of 10 identified genes can give
rise to MDS, and it is expected that more will be identi-
fied. Most mutated genes causing MDS are involved in
nucleotide synthesis, and can be identified by PCR or
Southern blotting [73]. MDS is one of the more com-
mon mitochondrial-associated metabolic disorders, and
has been identified as the underlying cause of mitochon-
drial dysfunction in 11% of children less than 2 years
presenting symptoms. Most cases are fatal, and currently
no treatment exists, though some symptoms are im-
proved with CoQ treatment. Given its relative frequency,
and severity of symptoms, the investigation of mutated
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is currently a popular field among researchers [74].
MNGIE
Along with CoQ deficiency, MNGIE is a well-character-
ized mitochondrial-associated disease for which a
clinical treatment has been identified. Mitochondrial
neurogastrointestinal encephalomyopathy (MNGIE) is a
rare mitochondrial disease, reported in about 100 cases,
which arises in patients carrying a recessive mutation in
the TYMP gene, causing a deficiency in thymidine phos-
phorylase [75]. Like other mitochondrial disorders,
MNGIE presents a wide range of symptoms in patients,
including muscle weakness, ptosis, peripheral neur-
opathy, gastrointestinal dysfunction, leukoencephalo-
pathy (i.e. defects in the white matter in the brain),
cachexia (i.e. loss of weight, muscle atrophy, fatigue,
etc.), and often results in mtDNA depletion [69]. The
disease progresses rapidly, with an onset around age 19,
and often leads to fatality, with an average lifetime of
37 years when left untreated [76].
Mutations in TYMP lead to a deficiency of thymidine
phosphorylase. Thymidine phosphorylase is required for
the assembly of nucleotides, namely the processing of
thymidine and deoxyuridine into thymine and uracil,
respectively. The thymidine phosphorylase deficiency
resulting from MNGIE leads to the accumulation of thy-
midine and deoxyuridine, detectable by HPLC [77]. It is
believed that due to this accumulation, there is an imbal-
ance in the nucleotide pool available in mitochondria for
mtDNA replication and transcription, and this leads to
mtDNA instability and degradation [78]. Research in the
treatment of this disease has focused on removing
the excess pools of thymidine and deoxyuridine from
the blood of MNGIE patients. Therapies such as
hemodialysis [79] and platelet administration [80] have
shown to be effective in reducing blood plasma levels of
these two nucleosides, and the subsequent alleviation of
symptoms. Most recently, it has been proposed that allo-
genic hematopoietic stem-cell transportation (AHSCT)
would be most effective in treating MNGIE, with
transplanted cells of a healthy genetic background re-
sponsible for restoring the proper dNTP pool balances.
Treatment for MNGIE using AHSCT is currently in
planning for clinical trials [69].
POLG mutations
As described earlier, given the critical metabolic func-
tions of its gene products, mtDNA maintenance and
replication is essential for proper mitochondrial func-
tion. It was originally thought that given the molecule’s
small size and high susceptibility to loss-of-function mu-
tations, mutations in mtDNA would underlie most mito-
chondrial pathologies. However, pathology arising fromPOLG/POLG2 mutations is one example of a mitochon-
drial-associated disease caused by mutation of a nuclear
gene. The replicative polymerase in mitochondria is the
mtDNA polymerase γ, made of two subunits encoded by
the POLG and POLG2 genes. In humans, POLG and
POLG2 are located on nuclear chromosomes 15 and 17,
respectfully. Mutations in POLG/POLG2 can be inhe-
rited or spontaneous, and other chemical modification
or inhibition of the polymerase itself (e.g. induced by
anti-HIV drugs) also leads to similar symptoms [81]. To
date, around 200 disease-associated POLG/POLG2
mutations leading to ETC dysfunction have been
reported and catalogued in a POLG mutation database
(http://tools.niehs.nih.gov/polg/).
Mutations in POLG/POLG2 often lead to mtDNA de-
pletion, with symptoms similar to MDS or MNGIE [82].
It is also documented that mutations affecting genes en-
coding other proteins necessary for replication (e.g. fac-
tors at the replication fork) also lead to mtDNA
depletion [83]. It is estimated that 12.48 per 100,000
adults and children have or are at risk to have a develop
mitochondrial disorder, and that 25% of those adults will
be found to have POLG mutations [84]. Given that ~2%
of the population carries harmful POLG mutations [85],
and given the relatively high frequency and severity of
this disease, future research into possible therapies is
also receiving a great deal of attention [86].
Mitochondrial dysfunction in type 2 diabetes
As of 2011, it is reported that 8.3% of the U.S. American
population suffers from diabetes; some 90% of which have
adult-onset type 2 diabetes (http://www.diabetes.org/).
The hallmark characteristic of type 2 diabetes is the ele-
vated level of blood glucose, caused by insulin deficiency
and insulin resistance [87]. The biological role of insulin,
secreted by pancreatic β-cells, is to stimulate glucose up-
take from the blood into target cells that require carbo-
hydrates for energy, including in the liver and skeletal
muscles. Though this disease arises from a complex set
of factors including genetic predisposition and lifestyle,
mitochondrial dysfunction has been identified within
various aspects in the pathogenesis of this disease. A var-
iety of molecules have been associated with contributing
to insulin resistance, when target cells no longer respond
to insulin signals to take up glucose from the blood,
resulting in high blood glucose and energy-deprived tis-
sues. Among these, fatty acids stand as prominent inhib-
itors of glucose uptake [88]. In skeletal muscle, increased
levels of fatty acids in blood plasma result in increased
intracellular acyl-CoA concentrations, activating an
intracellular signal cascade ultimately ending with the
suppression of insulin-dependent glucose transport [89].
It is believed that mitochondrial functional defects play a
key role in the development of insulin resistance. First,
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sult in increased fatty acid levels, contributing to fatty
acid-induced insulin resistance [90]. The causes for de-
fects in β-oxidation are thought to be spontaneous
mtDNA mutations that accumulate upon ageing [91].
Additionally, it may be that such mutations impair the
ATP-generating ability of mitochondria, which in turn
leads to a deficit of ATP, which is required for the trans-
port of glucose and insulin. One study found that mito-
chondria in skeletal muscle cells are smaller in number
and size and exhibit reduced ETC activity in patients
with type 2 diabetes, supporting the hypothesis of
inherited mitochondrial defects in type 2 diabetes [92].
While impaired mitochondrial β-oxidation leading to
insulin resistance is perhaps the most well supported
example of mitochondrial involvement in type 2 dia-
betes, a variety of other hypotheses exist. For example,
some studies support that pancreatic β-cell dysfunction
(i.e. impaired insulin production) contributes more to
pathogenesis than insulin resistance [93]. This is sup-
ported by a diabetes-associated mtDNA mutation in a
gene encoding a tRNA, leading to reduced insulin secre-
tion [94]. Additionally, mitochondria in type 2 diabetes
are suspected to be involved in numerous aspects of dis-
ease pathogenesis as well as responsible for some down-
stream effects after onset [95,96]. Importantly, at the
core of mitochondrial involvement in type 2 diabetes, as
well the majority of all mitochondrial-associated meta-
bolic diseases, is defects in ETC activity or fatty acid
oxidation. Therefore, ongoing research into therapies for
other mitochondrial-associated diseases is also likely to
have implications for treating certain aspects of type 2
diabetes, and vice versa.
Altered mitochondrial function in cancer
In addition to strictly metabolic disorders, mitochondrial
activity is affected in cancer patients. Often, tumor progres-
sion is associated with increased mitochondrial respiration
(due to rapidly growing cells) and therefore increased ROS
production. With increased ROS production comes an in-
creased risk of mtDNA mutation. MtDNA mutations are
thus a hallmark of many cancer patients. A large portion of
mutations occurs in the noncoding D-loop region of the
mtDNA, which is responsible for the initiation of replica-
tion. It appears that mtDNA mutations may not only be
consequences of tumorigenesis, but may aid in the process,
evidenced by a high correlation between stage of progres-
sion and specific mtDNA mutations [97].
Since the D-loop region is required for polymerase
binding and regulation of initiation of replication, it is
thought that these mutations frequently inhibit mtDNA
replication [97]. Indeed, it has been documented that
low mtDNA copy number is a characteristic feature of
numerous cancers including renal cell carcinoma [98],lung cancer [99,100], and breast cancer [101]. The cor-
relation between low mtDNA copy number and how
that may benefit cancer cell survival remains to be eluci-
dated. More recent research into mitochondria in cancer
cells has identified other variations in mitochondrial
function, such as the inhibition of mitochondrial calcium
uptake to promote cancer cell survival [102]. Recently it
was reported that mitochondrial miRNAs may also play
a role in modulating mitochondrial function and ener-
getic in cancer situations, in which miRNA regulation is
altered [103,104]. Further research into mitochondrial
variation in tumor progression will likely provide the
clinical community with new biomarkers for following
tumorigenesis as well as novel drug targets.
The role of mitochondrial dysfunction in heart failure
In a mechanism similar to mitochondrial dysfunction in
cancer, mitochondrial dysfunction has also been impli-
cated in heart failure [105]. The role of mitochondria in
cardiac muscle is paramount due to its function as an
organ of high-energy demand. Previously, studies on
patients with chronic heart disease revealed decreased
ETC complex activity, and identified a non-pathological
point mutation in the mtDNA-encoded cytochrome b
gene [106,107]. It is believed that a key event in the on-
set of heart failure is impaired blood flow both to and
within the heart. Impaired heart flow leads to reduced
oxygen availability at the ETC of cardiac mitochondria;
since oxygen is the final electron acceptor in the ETC, a
deficit of oxygen leads to the accumulation of electrons
at ETC complexes. Accumulation of electrons at ETC
complexes induces ROS production, which serves as a
stress response to signal that oxygen availability is low
[108]. ROS production, however, leads to mtDNA dam-
age and mutations. Accordingly, mtDNA mutations are
frequently observed in heart failure, leading to impaired
ETC activity, and in some cases mtDNA loss and loss of
mitochondrial mass [109].
Mitochondrial dysfunction caused by the accumulation
of ROS is characteristic of heart failure and other mito-
chondrial diseases. As such, it has been proposed that
mitochondrial dysfunction can be alleviated by adminis-
tering patients antioxidant compounds, which act as
ROS scavengers and thereby reduce their harmful effects
and reduce the frequency of mtDNA mutations [110].
Only one clinical trial with antioxidants has been carried
out, with the goal of alleviating mitochondrial defects in
Parkinson’s disease [17,110]. The trial was unsuccessful,
largely due to the difficulty in targeting the compound
to mitochondria. Nonetheless, recent studies in animals
[111] and cell culture models [112] have successfully de-
livered antioxidant compounds or enzymes to mitochon-
dria, and observed a decrease in ROS-associated defects.
Thus, the use of antioxidants seems to be a promising
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tion, but with much work still ahead before human ther-
apies will be available.
While the role of mitochondria in heart failure is more
downstream than in other metabolic diseases discussed
here, mitochondrial dysfunction comprises a key step in
the final stages of heart failure. Therapies targeting mito-
chondrial biogenesis and oxidative stress to treat heart
disease have made significant advances in comparison to
other mitochondrial-associated diseases, with mitochon-
dria standing as promising targets for treatment [113].
Conclusion
By classical definition, the core function of the mito-
chondrion is to act as the metabolic hub of the cell. In-
deed, as we have discussed here, when mitochondrial
respiratory activity becomes impaired, symptoms are vis-
ible on a systemic level. However, recent research has
found that mitochondria are involved in many other
additional processes, which also have the ability to influ-
ence mitochondrial function and dynamics and therefore
may give rise to disease. New treatments and therapies
for mitochondrial-associated diseases are now under
development; and while much work remains, the identi-
fication of new executors of metabolic disease has
renewed attention in developing treatments for many of
these disorders [114,115]. The next years of research
into further understanding mitochondrial dynamics and
non-canonical roles are sure to lead to new connections
between defects in mitochondria and defects in other
cellular processes, and provide new possibilities for de-
veloping therapies.
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